行情

INO

INO

Inovio制药
NASDAQ

实时行情|Nasdaq Last Sale

2.450
-0.070
-2.78%
盘后: 2.450 0 0.00% 16:00 11/11 EST
开盘
2.480
昨收
2.520
最高
2.500
最低
2.410
成交量
80.87万
成交额
--
52周最高
5.47
52周最低
1.915
市值
2.43亿
市盈率(TTM)
-2.0200
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

INO 新闻

  • Inovio up 20% on positive INO-5401 data
  • seekingalpha.6天前
  • Inovio Pharmaceuticals (INO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  • Zacks.6天前
  • ADBE, NIO among premarket gainers
  • Seeking Alpha - Article.6天前
  • Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (GBM) Study with INO-5401 In Combination with PD-1 Inhibitor Libtayo® (cemiplimab)
  • PR Newswire.6天前

更多

所属板块

生物技术和医学研究
-0.51%
制药与医学研究
-0.43%

热门股票

名称
价格
涨跌幅

INO 简况

Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.
展开

Webull提供Inovio Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。